Vir Biotechnology
VIR
VIR
208 hedge funds and large institutions have $901M invested in Vir Biotechnology in 2024 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 71 increasing their positions, 67 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
208
Holders Change
+3
Holders Change %
+1.46%
% of All Funds
3.02%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
31
Increased
71
Reduced
67
Closed
27
Calls
$3.04M
Puts
$2.7M
Net Calls
+$342K
Net Calls Change
-$1.01M
Top Buyers
| 1 |
Bank of America
Charlotte,
North Carolina
|
$11.5M |
| 2 |
Citigroup
New York
|
$11.4M |
| 3 |
Barclays
London,
United Kingdom
|
$10.3M |
| 4 |
O
OrbiMed
New York
|
$6.48M |
| 5 |
Citadel Advisors
Miami,
Florida
|
$34.5M |
Top Sellers
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
$1.11M |
| 2 |
Morgan Stanley
New York
|
$23.7M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
$1.45M |
| 4 |
TC
TwinBeech Capital
Purchase,
New York
|
$0 |
| 5 |
BlackRock
New York
|
$168M |
